Licensing routes to obtain a marketing authorisation for a medicine in the UK, GB or NI post Brexit

Last updated: 30 January 2025 To see updates, click on the ‘+’ sign below. Post Brexit, there are several routes to obtain a marketing authorisation in the United Kingdom (UK), Great Britain (England, Scotland and Wales) (GB) or Northern Ireland…

Read MoreLicensing routes to obtain a marketing authorisation for a medicine in the UK, GB or NI post Brexit

Learning from case law: Outcome of appeal request concerning SPC applications in the case of Halozyme Inc. vs the UK Intellectual Property Office

This is an attempt to present the facts leading to the outcome of the appeal request concerning Supplementary Protection Certificates (SPCs) in the case of Halozyme Inc. vs the UK Intellectual Property Office (IPO). The parties concerned Halozyme Inc. vs…

Read MoreLearning from case law: Outcome of appeal request concerning SPC applications in the case of Halozyme Inc. vs the UK Intellectual Property Office

Learning from Case Law: Mylan IRE Healthcare v European Commission (Case C-237/22) concerning orphan medicinal products

Last updated: 10 January 2025 To view updates, click on the ‘+’ sign below. This post is an attempt to to provide information on Case C-237/22 concerning Mylan IRE Healthcare v European Commission, including clarification of the concepts of “Significant…

Read MoreLearning from Case Law: Mylan IRE Healthcare v European Commission (Case C-237/22) concerning orphan medicinal products